Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kyongbo Pharmaceutical Co., Ltd. (214390:KRX), powered by AI.
Kyongbo Pharmaceutical Co., Ltd. is currently trading at ₩6,770. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Kyongbo Pharmaceutical Co., Ltd. on Alpha Lenz.
Kyongbo Pharmaceutical Co., Ltd.'s P/E ratio is 34.9.
“Kyongbo Pharmaceutical Co., Ltd. trades at a P/E of 34.9 (premium valuation) with modest ROE of 3.2%. 3Y revenue CAGR of 11.8% highlights clear growth momentum.”
Ask for details →Kyongbo Pharmaceutical Co., Ltd. is a prominent pharmaceutical company engaged in the research, development, and manufacture of medical products. Its primary function is to create and supply a wide range of pharmaceutical solutions, aiming to enhance human health and well-being. The company specializes in producing a variety of medications, including antibiotics, cardiovascular drugs, and gastroenterological products, reflecting its commitment to addressing diverse medical needs. Kyongbo Pharmaceutical Co., Ltd. plays a significant role in the healthcare sector, impacting both domestic and international markets with its high-quality pharmaceutical offerings. Founded with a mission to improve healthcare outcomes, it continuously invests in innovation and clinical research to ensure the efficacy and safety of its products. As a key player in the pharmaceutical industry, Kyongbo Pharmaceutical Co., Ltd. contributes to the availability of essential medicines, supporting the global healthcare infrastructure and helping meet the rising demand for effective health solutions.
“Kyongbo Pharmaceutical Co., Ltd. trades at a P/E of 34.9 (premium valuation) with modest ROE of 3.2%. 3Y revenue CAGR of 11.8% highlights clear growth momentum.”
Ask for details →Kyongbo Pharmaceutical Co., Ltd. (ticker: 214390) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $161.8B.
The current price is ₩6,770 with a P/E ratio of 34.89x and P/B of 1.11x.
ROE is 3.19% and operating margin is 4.38%. Annual revenue is $238.6B.